Brian Warrington pursued a career in drug discovery, primarily as a medicinal chemist with a strong interest in biology for over 50 years, making some key contributions to several significant drugs. Following retirement in November 2005 from his final industrial position as Vice President, Technology Development, GlaxoSmithKline UK he has followed an independent career as co-founder of BB Consultants Ltd, a Life Sciences consulting company. Through this he continues to actively consult on discovery technologies and/or serve on the Boards of clients ranging from large pharmaceutical companies and small start-ups in the UK and the USA. He has also maintained strong personal contacts with academia and the public sector serving as a visiting professor at Hull and Durham universities, as a member of the International Advisory and Commercialisation Panels of the University of Strathclyde and through positions on Government advisory panels. Dr Warrington holds a Ph.D. from the University of London, is a Fellow of the Royal Society of Chemistry and a Chartered Chemist. He has also received the ALA Lab Automation Achievement Award and the Royal Society of Chemistry Millennium Medal recognising his contributions to high throughput discovery technologies and pioneering work in chemical microfluidics.